6 Best Peptides for the Gut-Brain Axis

What to Know Before Choosing a Peptide for the Gut-Brain Axis

The gut-brain axis is a two-way communication network linking your central nervous system and the enteric nervous system woven through your gastrointestinal tract. It runs through neural signals carried by the vagus nerve, hormone-like peptides released into the bloodstream, immune messengers, and microbial metabolites produced by the gut microbiome. When that network is running well, your gut and brain stay coordinated. When it breaks down, the symptoms tend to straddle both systems: digestive complaints paired with anxiety, brain fog that tracks closely with gut inflammation, mood shifts that follow gut flares.

Peptides that support this axis work at one or more of its layers. Some repair the physical gut barrier, reducing the inflammatory load that eventually reaches the brain. Some modulate immune signaling. Some work from the brain side, calming the stress and anxiety pathways that in turn drive gut dysfunction. A few address more than one of those layers at once.

Every compound in this guide earned its place because people use it, or are actively discussing using it, for gut-brain axis support. That is the only test for inclusion here. FDA-approved, telemedicine-prescribed, and research-only compounds are all eligible. Evidence strength is stated honestly inside each entry rather than used as a filter for inclusion. A compound with only animal research belongs here, described as such, right alongside one with human trial data. Leaving out a widely-used compound because its literature is thin would make this guide less useful, not more responsible.

The entries are numbered, but the numbers are a spine for the list, not a ranking. The order reflects how prominently each compound appears in research and documented real-world use for this goal, not a recommendation of one compound over another for your specific situation. Personalizing that choice is what the MyPeptidePal app is built to help you do.

1. BPC-157: The Broadest Gut-Brain Repair Signal

BPC-157 stands for Body Protection Compound-157. It is a synthetic 15-amino acid peptide derived from a protein found in human gastric juice, and it consistently leads gut-brain axis discussions for one reason: it works on both sides of the axis simultaneously in ways no other compound in this category does.

On the gut side, BPC-157 promotes repair of the intestinal mucosal lining, the cellular layer that keeps gut contents from leaking into the bloodstream. It does this partly through angiogenesis, the growth of new blood vessels, which improves oxygen and nutrient delivery to damaged tissue. A healthier, more intact gut lining means less inflammatory material crossing into circulation, which reduces the inflammatory burden reaching the brain.

On the brain side, BPC-157 has shown neuroprotective effects in animal models, including reduced oxidative stress in neural tissue and enhanced neuronal survival. It also appears to influence neurotransmitter pathways, particularly serotonin and nitric oxide signaling. Serotonin is especially relevant here: roughly 90 percent of the body's serotonin is produced in the gut, and BPC-157 research in rodent models has shown region-specific effects on serotonin activity in brain regions involved in mood and motor control.

The honest evidence picture: the entire published evidence base for BPC-157 is preclinical. All of the tissue repair, neuroprotection, and neurotransmitter findings come from animal models and laboratory studies. One Phase I human trial was conducted but the data was never published in a peer-reviewed journal, which means it cannot be independently evaluated. No published human clinical trials exist for BPC-157 in gut-brain outcomes, depression, anxiety, or any neurological indication. What the research community and users are responding to is a strong preclinical story, not a clinical one.

Community reports add texture to that picture. Users in biohacking and functional medicine contexts describe reduced bloating, improved digestion, clearer thinking, and more stable mood. Some report initial side effects including headaches, nausea, and fatigue in the first few weeks. Some community members flag that extended high-dose use may push serotonin activity in an unfavorable direction, a caution worth noting even though it comes from user observation rather than controlled data. People with a history of cancer should be aware that BPC-157 may increase VEGF, a protein that signals the body to grow new blood vessels, which warrants a conversation with a qualified provider before use.

BPC-157's regulatory status has been in flux. The FDA classified it as a Category 2 bulk drug substance in 2023, restricting compounding pharmacy access. An announcement in early 2026 described a potential reclassification back to Category 1 that would restore that access, though as of this writing the reclassification had not been finalized. Anyone considering it should verify current status with a qualified prescriber.

2. KPV: Targeting the Gut Inflammation That Feeds the Brain

KPV is a tripeptide composed of just three amino acids: lysine, proline, and valine. It is derived from the C-terminal end of alpha-melanocyte-stimulating hormone, a peptide produced in the pituitary gland that plays a broad role in immune regulation. Its core action: it limits inflammatory signaling within the intestinal lining.

The gut-brain axis connection with KPV is primarily about reducing upstream inflammatory load. When the intestinal epithelium is inflamed, inflammatory molecules enter systemic circulation and can eventually reach the brain, contributing to the neuroinflammation that researchers associate with symptoms like brain fog, anxiety, and depression. KPV acts on epithelial immune signaling to reduce that inflammatory response at its source. It also appears to protect the epithelial barrier itself, helping maintain the layer that prevents inflammatory material from crossing into circulation in the first place.

The evidence base for KPV is preclinical. Animal model studies of intestinal inflammation have shown reductions in inflammatory markers and protection of the gut lining. No published human clinical trials have tested KPV specifically for gut-brain axis outcomes as of 2026. Its use in functional medicine translates that preclinical anti-inflammatory story to conditions like IBS, leaky gut, gastritis, and post-antibiotic gut disruption, with the assumption that a calmer gut produces downstream benefits for the brain.

KPV is commonly paired with BPC-157 in protocols aimed at gut repair, with the logic that BPC-157 promotes structural tissue healing while KPV addresses the immune-inflammatory driver. User-reported experience from functional medicine contexts describes reduction in gut symptoms and, secondarily, improvements in mood and clarity attributed to lowering the inflammatory noise coming from the gut. These observations come from user experience rather than controlled measurement.

3. Larazotide: Sealing the Gateway Between Gut and Brain

Larazotide, also called larazotide acetate, is an eight-amino acid synthetic peptide that works through a mechanism distinct from anything else on this list. Rather than repairing damaged tissue or quieting immune activity broadly, it targets the tight junctions between intestinal epithelial cells. Tight junctions are the protein structures that act as seals between cells, keeping the gut wall intact. When they loosen, gaps open, allowing bacterial fragments, toxins, and inflammatory molecules to enter the bloodstream, a pattern commonly called intestinal hyperpermeability or leaky gut.

The relevance to the gut-brain axis is direct. One of the main routes by which gut dysfunction triggers brain inflammation is through the translocation of these molecules into circulation, where they can trigger systemic immune responses that affect neural tissue. Larazotide addresses that route by stabilizing the tight junctions and preventing the initial breach.

What distinguishes Larazotide from others in this category is that it has been through human clinical trials. Studies in human participants have tested its effects on intestinal permeability and barrier function, including trials in people with irritable bowel syndrome. The evidence is emerging rather than definitive: the trials conducted support the mechanism and show measurable effects on barrier markers, but Larazotide is not broadly approved for any indication, and the pathway from those trial findings to routine clinical use has not been completed. It is more accessible through functional medicine practitioners and research contexts than through conventional prescribing.

For someone whose gut-brain axis problems appear to be rooted in permeability rather than inflammation or tissue damage as the primary driver, Larazotide occupies a mechanistically distinct position. It is not interchangeable with BPC-157 or KPV; it targets an earlier step in the chain.

4. Thymosin Alpha-1: Resetting the Immune Tone Behind Both Systems

Thymosin Alpha-1 is a 28-amino acid peptide derived from the thymus gland, the organ responsible for training immune cells early in life. Its primary action is systemic immune regulation: it helps restore balance to an immune system that has shifted toward chronic low-grade activation.

The connection to the gut-brain axis runs through the immune pathway. The gut houses a significant portion of the body's immune tissue, and when gut health is disrupted, immune dysregulation can produce a background inflammatory state that affects both gut function and brain function. Chronic cytokine activity, the chemical signaling of a persistently activated immune system, is increasingly linked to cognitive symptoms and mood disturbance. Thymosin Alpha-1 works at that systemic level, helping to dampen the chronic immune activation that feeds into both sides of the axis.

This compound has more clinical history than most others in the research peptide category. It has been used clinically in some countries for immune-related conditions including certain viral hepatitis indications, giving it a longer human safety record than purely preclinical compounds. For gut-brain axis use specifically, the evidence is in an emerging phase: the mechanism is supported by published research on immune regulation, and its broader international clinical history provides more comfort with the safety profile than is typical for research peptides in this category. Formal clinical trials for gut-brain outcomes have not been published as of 2026. Its use for this goal is based on translating its documented immunomodulatory action to the specific context of gut-brain immune dysregulation.

Practitioners using Thymosin Alpha-1 for gut-brain support tend to position it for cases where chronic immune activation is the dominant pattern, rather than acute gut tissue damage or permeability as the primary driver.

5. Selank: Working the Brain Side of the Axis

Selank is a synthetic seven-amino acid peptide developed in Russia as an analog of tuftsin, a naturally occurring peptide involved in immune and nervous system function. It is classified as an anxiolytic, meaning it reduces anxiety, and it works through mechanisms relevant to the brain side of the gut-brain axis rather than the gut side directly.

Its primary actions include modulating gene expression related to neurotransmission, enhancing activity at GABA-A receptors (GABA being the main inhibitory neurotransmitter in the central nervous system, functioning as a brake on neural excitation), and dampening neuroinflammatory cytokine signaling. These actions reduce the anxiety and stress activation that, through the gut-brain axis, directly drives gut dysfunction. The relationship is bidirectional: gut inflammation can drive anxiety, and anxiety-driven activation of the stress hormone system can worsen gut inflammation. Selank addresses the second direction.

The evidence base for Selank in Western clinical literature is limited. Some clinical research was conducted in Russia, where Selank has been used in clinical settings for anxiety and cognitive conditions, but those studies are not widely replicated in peer-reviewed Western journals. In the US and most Western markets, it is a research peptide, and the evidence for its gut-brain axis use specifically is largely community-reported from user protocols and functional medicine contexts.

That community-reported use is consistent and recurring. Selank appears regularly in discussions of peptide protocols for anxiety-driven gut symptoms, cognitive clarity, and the brain-fog-gut-distress overlap. People who have used it describe reductions in baseline anxiety and, separately, improvements in gut symptoms they attribute to that change. Whether that pattern reflects the compound's mechanism or other variables cannot be determined from observational reports. What is accurate is that this compound is actively discussed and used for this goal, which is why it belongs on this list.

6. VIP: The Nervous System's Own Gut-Brain Messenger

VIP stands for Vasoactive Intestinal Peptide. Unlike the other compounds in this guide, VIP is not a synthetic research chemical developed for therapeutic use. It is an endogenous neuropeptide, one the body produces itself, found throughout the gut, pancreas, and nervous system. Understanding why it belongs here requires a brief look at what it does naturally.

VIP functions as both a neurotransmitter and a neuromodulator in the enteric nervous system, the network of neurons embedded in the walls of the gastrointestinal tract. It regulates gut motility (the movement of material through the digestive system), controls secretion of digestive fluids, governs blood flow to gut tissue, and has potent anti-inflammatory properties that shift the cytokine profile of gut immune tissue toward lower inflammation. VIP receptors, designated VPAC1 and VPAC2, are expressed in gut tissue and in brain regions including the hypothalamus and limbic system, the structures central to stress response, mood, and autonomic nervous system tone.

VIP belongs in gut-brain axis discussions because it sits at the intersection of enteric nervous system function, gut immune tone, and central nervous system signaling. Researchers and clinicians interested in modulating this axis have begun exploring whether VIP-based or VIP-mimicking approaches could support the system, particularly in conditions involving gut motility disorders and inflammatory gut conditions with neurological components.

The evidence for exogenous VIP administration as a gut-brain axis therapy is at an early stage. VIP's physiological role is established across decades of published research, but the work into administering it as a therapeutic compound for gut-brain outcomes is newer and less developed than the preclinical bodies of work behind BPC-157 or KPV. The accurate framing is that VIP is discussed and explored in this context, with its endogenous biology providing the mechanistic rationale, but robust clinical trial data for its use as an administered therapeutic peptide for gut-brain outcomes is not yet available.

How These Peptides Compare

Frequently Asked Questions

Are these peptides legal to use for gut-brain axis support?

It depends on the compound and how you access it. BPC-157 sits in a regulatory gray zone: the FDA restricted compounding pharmacy access in 2023, and a potential reclassification announced in early 2026 had not been finalized as of this writing. KPV, Selank, Thymosin Alpha-1, and VIP are research compounds in the United States, and the legality of obtaining them outside a licensed clinical or research context is not straightforward. Anyone considering these compounds should work with a qualified healthcare provider and verify current regulatory status before proceeding.

How do I know which of these fits my situation?

The compounds in this guide work at different layers of the gut-brain axis. BPC-157 and KPV address gut tissue repair and local inflammation. Larazotide targets intestinal permeability specifically. Thymosin Alpha-1 works at the systemic immune level. Selank addresses the brain-side anxiety and stress pathways. VIP is relevant when gut motility and enteric nervous system signaling are central to the picture. Identifying the right starting point depends on where the axis is actually breaking down, and that assessment benefits from working with a qualified provider rather than self-diagnosing from a list.

How long before any of these compounds shows an effect?

This varies widely by compound and by what you are trying to address. Community-reported experience with BPC-157 describes initial changes in gut symptoms within one to three weeks, with the most commonly reported meaningful shifts arriving somewhere in the two-to-six-week range. Compounds working at the immune or systemic level, like Thymosin Alpha-1, are generally described as taking longer. These timelines reflect patterns in user-reported observations, not established clinical benchmarks, and individual responses vary considerably.

Is leaky gut the same as gut-brain axis dysfunction?

They are related but not the same thing. The gut-brain axis is the full bidirectional communication system between the gut and the brain, operating through neural, hormonal, immune, and microbial pathways. Leaky gut, or intestinal hyperpermeability, is one specific mechanism by which gut dysfunction can affect the brain: when tight junctions between gut cells loosen, inflammatory molecules enter the bloodstream and can contribute to brain inflammation. Leaky gut is one entry point into gut-brain disruption, which is why Larazotide, with its tight-junction-focused mechanism, is relevant to gut-brain health even though its action is entirely gut-focused.

Can any of these peptides be combined?

BPC-157 and KPV are frequently combined in functional medicine protocols, based on the logic that their mechanisms address different aspects of gut repair without overlap. Adding Selank for the anxiety component is also discussed in community protocols. Whether any combination is appropriate depends on individual circumstances, and layering multiple research peptides carries compounded uncertainties, since interactions between them have not been formally studied. This is a conversation to have with a qualified provider who understands both the mechanisms and your specific history.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for gut-brain axis support in one place.